These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 26469914)

  • 1. Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series.
    Li SH; Hsieh MH; Fang YF
    Medicine (Baltimore); 2015 Oct; 94(41):e1739. PubMed ID: 26469914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases.
    Li SH; Liu CY; Hsu PC; Fang YF; Wang CC; Kao KC; Tseng LC; Yang CT
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):81-89. PubMed ID: 29172778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
    Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
    Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.
    Hoffknecht P; Tufman A; Wehler T; Pelzer T; Wiewrodt R; Schütz M; Serke M; Stöhlmacher-Williams J; Märten A; Maria Huber R; Dickgreber NJ;
    J Thorac Oncol; 2015 Jan; 10(1):156-63. PubMed ID: 25247337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.
    Saxon JA; Sholl LM; Jänne PA
    J Thorac Oncol; 2017 May; 12(5):884-889. PubMed ID: 28088511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.
    Zhang X; Maity T; Kashyap MK; Bansal M; Venugopalan A; Singh S; Awasthi S; Marimuthu A; Charles Jacob HK; Belkina N; Pitts S; Cultraro CM; Gao S; Kirkali G; Biswas R; Chaerkady R; Califano A; Pandey A; Guha U
    Mol Cell Proteomics; 2017 May; 16(5):891-910. PubMed ID: 28331001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.
    Wu SG; Liu YN; Tsai MF; Chang YL; Yu CJ; Yang PC; Yang JC; Wen YF; Shih JY
    Oncotarget; 2016 Mar; 7(11):12404-13. PubMed ID: 26862733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.
    Ibrahim U; Saqib A; Atallah JP
    Lung Cancer; 2017 Jun; 108():45-47. PubMed ID: 28625646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.
    Yuan Y; Tan C; Li M; Shen H; Fang X; Hu Y; Ma S
    World J Surg Oncol; 2012 Nov; 10():235. PubMed ID: 23134665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
    Lu S; Shih JY; Jang TW; Liam CK; Yu Y
    Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.
    Huang YH; Hsu KH; Chin CS; Tseng JS; Yang TY; Chen KC; Su KY; Yu SL; Chen JJW; Chang GC
    Cancer Res Treat; 2022 Apr; 54(2):434-444. PubMed ID: 34352999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
    Schuler M; Wu YL; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist LV; Massey D; Zazulina V; Yang JC
    J Thorac Oncol; 2016 Mar; 11(3):380-90. PubMed ID: 26823294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFR-mutant (Exon18:G719S) lung adenocarcinoma as a second-line chemotherapy.
    Tamiya M; Shiroyama T; Nishihara T; Nishida T; Hayama M; Tanaka A; Morishita N; Suzuki H; Okamoto N; Hirashima T
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e531-e533. PubMed ID: 28004883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
    Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
    BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.
    Watanabe M; Oizumi S; Kiuchi S; Yamada N; Yokouchi H; Fukumoto S; Harada M
    Intern Med; 2018 Apr; 57(7):993-996. PubMed ID: 29225262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.
    Pirazzoli V; Ayeni D; Meador CB; Sanganahalli BG; Hyder F; de Stanchina E; Goldberg SB; Pao W; Politi K
    Clin Cancer Res; 2016 Jan; 22(2):426-35. PubMed ID: 26341921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.